^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GC007G

i
Other names: GC007G, donor-derived anti-CD19 chimeric antigen receptor cell therapy , Donor derived CD19-targeted CAR-T cell therapy, Donor CAR-19, Anti-CD19 Allo-CAR-T Cells
Associations
Trials
Company:
AstraZeneca
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
11ms
Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. (PubMed, EClinicalMedicine)
GC007g expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Gracell Biotechnologies Inc.
P1 data • Journal • CAR T-Cell Therapy
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
GC007G
over1year
DONOR-DERIVED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE 1 TRIAL (EHA 2023)
Donor-derived CD19 CAR T-cell expanded and induced durable remission in patients with B-ALL relapsed after allo-HSCT, with manageable safety profiles. Phase 2 clinical trial of GC007g is currently recruiting. B cell acute lymphoblastic leukemia, CAR-T
P1 data • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule)
|
CD19 expression
|
GC007G